Synergys Biotherapeutics, Inc. logo

Synergys Biotherapeutics, Inc.

Synergys Biotherapeutics, Inc is a preclinical-stage biotech company, developing antibody therapeutics for the treatment of cancer.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.synergysbio.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1945 Arbol Grande, CA, 94595
Walnut Creek
United States
Email
Contact Number
+1 925-575-0181

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Synergy drug discovery platform is based on Antibody-Targeted Endostatin Payload (ATEP) technology. ATEP is a fully biological payload that genetically fuses a highly efficient variant of endostatin, endostatin-P125A, to an antibody in a specific manner for efficient delivery to anti-angiogenic therapeutic.

In Sep 2017, Synergys received a Phase I grant worth $ 300K from the National Cancer Institute under the Small Business Innovation Research (SBIR) program of the National Institutes of Health for the development of SYN001.